semaj83/ctmatch_classification huggingface dataset:
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetic Foot Ulcer Type 2 Diabetes Male or female, age ≥ 18 Type 2 Diabetes A break in the skin on the foot ≥ 0.5cm2 and is Grade 1 or 2 as defined by the Wagner grading system Hemoglobin A1c ≥ 5.9% Ability to provide written informed consent  Any experimental drugs taken orally or topically within 4 weeks of study entry Malignant disease at/or in proximity to the DFU Target wound of malignant origin Failure to satisfy at least one criterion for one of the two study groups
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Eczema Healthy male or female ≥ 18 and ≤ 70 years of age Body mass index (BMI) ≥ 20 and ≤ 35 kg/m2 Subjects with mild to moderate eczema; determined at screening visit Judged by the Investigator to be in general good health on the basis of medical history Agree to use the Study-supplied cleanser and moisturizer as the only body cosmetic applied to irritated skin Agree to stop all medications and supplements during the entire length of the study Females of child bearing potential must agree to use appropriate birth control methods during the entire study period Agree not to initiate any new exercise or diet programs during the entire study period Agree not to change their current diet or exercise program during the entire study period Understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator  Clinically significant renal, hepatic, endocrine (including diabetes mellitus), cardiac, pulmonary, pancreatic, neurologic, hematologic, or biliary disorder Known allergy or sensitivity to Herbal products History or presence of cancer in the prior two years, including any skin cancer or suspicious lesions Recent history of alcoholism (within 12 months) or strong potential for alcohol or substance abuse Participation in a clinical study with exposure to any non-registered drug product within 30 days prior Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk. Including subjects who are Bed or wheelchair-bound Pregnant, lactating, or unwilling to use adequate contraception during the duration of the study Smoking must be nonsmoker for at least 12 weeks prior to screening
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Central Retinal Vein Occlusion Patients age 18-80 years with a documented CRVO who treated by Avastin for more than 12 months Patients who signed an informed consent form  Patients with Carotid stenosis of more than 70% Anemia of < 10mg/Dl Patients with chest X ray pathology which cannot be admitted to hyperbaric chamber treatment Patients with claustrophobia or that cannot decompress properly Patients with any malignant disease Patients with inability to sign informed consent
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Foot Ulcer, Diabetic Infection Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria Has at least 1 skin ulcer located on or below the malleolus that presents with the following clinical manifestations of a moderate or severe infection based on the Infectious Disease Society of America guidelines for the "Diagnosis and Treatment of Diabetic Foot Infections" (CID 2012; 54:132-173) (IDSA guidelines) has ≥ 2 manifestations of inflammation (local swelling or induration, erythema, local tenderness or pain, local warmth, purulent discharge (thick, opaque to white or sanguineous secretion) has ≥ 1 of the following characteristics: erythema > 2cm, or involving structures deeper than skin and subcutaneous tissues (e.g. abscess, osteomyelitis, septic arthritis, fasciitis) For patients with multiple infected ulcers, the ulcer with the highest Diabetic Foot Infection Wound score (DFI score) must be on or below the malleolus and all infected ulcers must be completely coverable using no more than 4 sponges (sponges cannot be cut) Has documented adequate arterial perfusion in the affected limb(s) (either palpable dorsalis pedis and posterior tibial pulses, or normal Doppler wave forms, a toe blood pressure ≥ 45 mm Hg or participation is approved by a vascular surgeon) Has received appropriate surgical intervention to remove all necrotic and infected bone if diagnosed with osteomyelitis Has received appropriate surgical debridement to remove all gangrenous tissue  Has a known history of hypersensitivity to gentamicin (or other aminoglycosides) Has a known or suspected hypersensitivity to bovine collagen Has an ulcer infection which, based upon the patient's known history of hypersensitivity and/or as otherwise in the opinion of the investigator, cannot be adequately treated with at least one of the empiric systemic antibiotic regimens allowed by this protocol Has an ulcer associated with prosthetic material or an implanted device Has received any systemic or topical antibiotic therapy for any reason within 7 days of randomization unless it was administered to specifically treat the infected ulcer(s) and only within 36 hours of randomization Requires or is likely to require treatment with any concomitant topical product or wound therapy before the first follow-up study visit Is severely immunocompromised, or likely to become severely immunocompromised during the study, in the opinion of the investigator Has a history of myasthenia gravis or other neurological condition where gentamicin use is contraindicated as determined by the investigator Has a history of epilepsy Has a history of alcohol or substance abuse in the past 12 months
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus, Type 2 Adults 18 years and older (to be confirmed by electronic health record) Individuals who have received a diagnosis for type 2 diabetes mellitus (T2DM) Enrolled as a patient in the Vanderbilt APPC or the Eskind Diabetes Clinic Registered My Health at Vanderbilt user Individuals currently being treated with oral and/or injectable diabetes medication (to be confirmed through electronic health record)  Non-English speakers (determined by a trained research assistant) Individuals with a severe hearing or visual impairment (determined subjectively by a trained research assistant) Individuals with delirium or a severe cognitive impairment (determined by a lack of orientation to person, place, and time) Individuals who report a caregiver administers their diabetes medications Individuals who report they do not have a mobile phone or computer with internet access Individuals unwilling and/or unable to provide written informed consent
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ulcer Wounds A signed and dated informed consent has been obtained from the subject Subject is able and willing to comply with study procedures Subject is able to comply with weekly visits Subject is 18 years of age or older There is presence of at least 50% or greater necrotic tissue (including slough and eschar) in the wound bed and a total wound surface area of > 1cm2 to < 64cm2 Subject will not have currently used parenteral or oral antibiotics except for UTI Diabetic subjects: HbA1c < 12.0 % within 90 days preceding enrollment Pre-albumin greater than 16 mg/dl within 90 days preceding enrollment Subject with a pressure ulcer must be currently receiving adequate pressure redistribution to the affected area via group 2 or 3 specialty bed, a static wheel chair cushion while patient is out of bed Subject with diabetic plantar surface ulcer will use an offloading boot if ambulatory  Steroid use >5mg daily Subject is unable to cooperate with offloading and/or compression recommendations ABI = or >0.8 if the wound is located on a lower extremity Wound has the presence of callus requiring sharp or surgical debridement within 3 days prior to randomization and/or needs debridement using any method other than the study agent throughout study treatment Subject has medical instability as deemed by the investigator Subject is pregnant Subject has participated in another clinical trial or wound dressing evaluation in the 30 days prior to enrollment
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Foot Ulcer Varicose Ulcer Patients with cutaneous leg ulcers due to diabetes mellitus, venous stasis and arterial insufficiency requiring healing or tissue debrided sent to managing their disease to regional general hospital No. 17, Instituto Mexicano del Seguro Social, Benito Juárez, Quintana Roo Patients of both sexes Patients over 18 years Patients that have basic laboratory at admission (complete blood count with differential) Patients with comorbidities associated as Diabetes Mellitus , Hypertension, stroke, heart disease, nephropathy, venous insufficiency and arterial insufficiency, etc  Hemodynamically unstable patients Patients with septic shock from any source Patients with deep skin ulcers with exposed some organ, data osteomyelitis, vascular-nervous exposure Patients with secondary cutaneous ulcer enteral fistula Patients with cutaneous ulcer or cancer tumors Patients with cutaneous ulcer with active bleeding Patients with cutaneous ulcer necrosis Patients with cutaneous ulcer leishmania, insect bite Patients with cutaneous ulcer burns Patients who do not accept their participation in the study through informed consent
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 0.5-85.0,  Xerosis Cutis Signed informed consent, or children whose parent(s) or guardian(s) have given their written informed consent for their child's participation in the study Child specific written informed consent, if over 7 years of age Subjects with a general good and stable health condition Subjects with clinically stable medical conditions Accept to abstain from sunbathing and solarium during the study Overall Dry Skin score (ODS) of 1 to 2 at arms and lower legs TEWL > 12 g/m2/h on the left mid volar forearm  Any dermatological condition or skin affection which may interfere with the study assessments, e.g. scars Suffering from porphyria Suffering from severe photodermatoses according to the judgment of the investigator Clinically significant, possibly unstable medical conditions such as metastatic tumor Currently having other malignant or benign tumors of the skin in the investigational area Any other acute or chronic pathology that may interfere with the study conduct in the investigator's opinion Known allergy or intolerance to any ingredients of the study product, e.g. propylene glycol Use of (medical) oil-containing bath additives or other oil-containing cleansers Current topical or systemic treatment affecting the skin, e.g. diuretics Treatment of dry and/or inflammatory skin conditions with topical corticosteroids during the 4 weeks before
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Infection Cohort 1: Diabetic hyperbaric patients with active, chronic infection Adult patients (ages 18-65) presenting for an anticipated course of at least 4 hyperbaric oxygen sessions for chronic clinical indications (possible indications diabetic lower extremity wounds or refractory osteomyelitis) Diabetes mellitus Current antibiotic use for active infection  Prior treatment with hyperbaric oxygen within the last 30 days Consistent vitamin C or vitamin E supplementation in the past year Active tobacco use Pregnancy Cohort 2: Hyperbaric patients without diabetes or active infection Adult patients (ages 18-65) presenting for an anticipated course of at least 4 hyperbaric oxygen sessions for chronic clinical indications (possible indications crush injury, acute peripheral arterial insufficiency, or radiation necrosis) Prior treatment with hyperbaric oxygen within the last 30 days Consistent vitamin C or vitamin E supplementation in the past year Active tobacco use Pregnancy
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Leg Ulcers Patient over 18 years old who has provided his/her written informed consent Patient who can be monitored by the same investigation team throughout the whole duration of the study Patient who agrees to wear an effective venous compression system every day, associated with the trial dressing Leg ulcer with an Ankle Brachial Pressure Index (ABPI) not less than 0.7 and not more than 1.3 Ulcer area > or equal to 5cm2 Ulcer duration > or equal to 6 months Ulcer presenting a the surface wound bed covered with 50% or more by sloughy tissue Moderately or heavily exudative ulcers  Clinical infection on the wound bed
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Diabetes Diabetes Complications Neuropathy Peripheral Neuropathy Diabetic Foot Ulcer Diabetes (according to AAFP diagnostic ) Presence of neuropathy with Loss of Protective Sensation (LOPS), as defined by any loss of sensation as per the assessments included in the Modified Neuropathy Disability Score (MNDS) Active plantar diabetic foot ulcer (Grade 1A, according to the University of Texas Wound Classification System , ) A minimum size ulcer ≥1cm2 and ≤ 12 cm2 post debridement at time of randomization If the subject has more than one ulcer, they should be identified and at least 2 cm apart The duration of the study ulcer is at least 30 days at the time of the screening visit Age >18 At least one palpable foot pulse Ability to understand all of the study requirements Life expectancy greater than the duration of the study  Weight > 400 lb (182 kg) Uncorrected visual impairment Active Infection Non-plantar ulcers on the ankle, posterior heel, or other location More than one active plantar ulcer Presence of severe ischemia (any of: absence of foot pulses, Ankle Brachial Index 0.6 > [ABI] > 1.2, capillary refill time > 5 seconds; see Appendix 3) Current participation in another clinical investigation of a medical device or a drug; or has participated in such a study within 30 days prior to this study Current smokers Active abuse of alcohol o Subject has a history of any of the following intercurrent illnesses or conditions that would compromise the safety of the subject or the normal healing process
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lower Limb Ulcers Patient is 18 years of age or older Patient has one of the following difficult-to-treat chronic ulcers in the lower limb 1. Neuropathic lower limb ulcer 2. Venous lower limb ulcer 3. Post traumatic lower limb ulcer 4. Post operative lower limb ulcer In case of Neuropathic foot grade according to University of Texas Classification 1A Wound area measurement ranging between 1-20cm2  Acute ulcer Multiple Ulcers on the lower limb Clinical evidence of infection in the soft tissue, joint and/or bone (osteomyelitis) as presented in the physical examination The wound is penetrating into deep structures and involves bone tendon or joint Wound has necrotic tissue Wound with sinus tracts HbA1c>12 Patients with any other skin disorder unrelated to the ulcer that is
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Diabetic Foot Ulcer Subject is between 18 years and 80 years of age Subject is diagnosed with Type I or Type II diabetes, and had defined as diabetic foot ulcers presence of wound for more than 4 weeks at the screening visit Ulcer located the foot, and ulcer size is between 1 cm2 and 25 cm2 Ulcer extends into the dermis, subcutaneous tissue, tendon or joint capsule (Wagner grade 1 or 2) Ulcer is free of necrotic debris Subjects had adequate circulation to ulcer as documented by either Palpation of pulses around ulcer using Doppler exam Ankle Brachial index (ABI) values ranging between 0.7 and 1.3, or Transcutaneous Oxygen Pressure (TcPO2) > 30 mmHg Subject is able to give written informed consent prior to study start and to comply with the study requirements  Ulcer is of non-diabetic pathophysiology The ulcer has increased or decreased in size by 30% or more during one week after the screening visit Subject is Human Immunodeficiency Virus (HIV) positive Subjects with severe hepatic deficiencies Subjects with a glycated hemoglobin A1c (HbA1c) level of > 15% Subject who are allergic or have a hypersensitive reaction to bovine-derived proteins or fibrin glue Subjects requiring intravenous (IV) antibiotics to treat the index wound infection Subjects who are currently receiving dialysis Subjects who are pregnant or breast-feeding Subjects who are unwilling to use an "effective" method of contraception during the study
Patient description: 64-year-old obese female with diagnosis of diabetes mellitus and persistently elevated HbA1c. She is reluctant to see a nutritionist and is not compliant with her diabetes medication or exercise. She complains of a painful skin lesion on the left lower leg. She has tried using topical lotions and creams but the lesion has increased in size and is now oozing.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus Diabetes patients who are users of CVD risk factor medications (antihypertensive therapies, antihyperlipidemics therapies, and oral antihyperglycemic therapies) Diabetes patients considered to be poorly adherent to CVD risk factor medications within the prior 12 months Diabetes patients who have not used the mail order pharmacy to fill any prescribed medications at least once in the prior 12 months
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bipolar Disorder Patients must have Acute bipolar I illness and be experiencing a manic or depressed episode at the time of study entry Required Current treatment with lithium carbonate